<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39360263</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Tracking temporal variations of fatality and symptomology correlated with COVID-19 dominant variants and vaccine effectiveness in the United States.</ArticleTitle><Pagination><StartPage>1419886</StartPage><MedlinePgn>1419886</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1419886</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1419886</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">We described how COVID-19 fatality and symptoms varied by dominant variant and vaccination in the US.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using the Restricted Access Dataset from the US CDC (1/1/2020-10/20/2022), we conducted a cross-sectional study assessing differences in COVID-19 deaths, severity indicators (hospitalization, ICU, pneumonia, abnormal X-ray, acute respiratory distress syndrome, mechanical ventilation) and 12 mild symptoms by dominant variant/vaccination periods using logistic regression after controlling for confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We found the highest fatality during the dominant periods of Wild (4.6%) and Delta (3.4%). Most severe symptoms appeared when Delta was dominant (Rate range: 2.0-9.4%). Omicron was associated with higher mild symptoms than other variants. Vaccination showed consistent protection against death and severe symptoms for most variants (Risk Ratio range: 0.41-0.93). Boosters, especially the second, provided additional protection, reducing severe symptoms by over 50%.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This dataset may serve as a useful tool to monitor temporospatial changes of fatality and symptom for case management and surveillance.</AbstractText><CopyrightInformation>Copyright © 2024 Lin, Liu, Qi, Trees, Gao, Friedman, Xue and Lawrence.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, School of Public Health, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Sociology and Demography, University of Texas at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Economics, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trees</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Epidemiology Branch, Division of Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Donghong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Sociology, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Xiaobo Romeiko</ForeName><Initials>XR</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, School of Public Health, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, School of Public Health, University at Albany, State University of New York, Albany, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wadsworth Center, New York State Department of Health, Albany, Albany, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">deaths</Keyword><Keyword MajorTopicYN="N">dominant viral variants</Keyword><Keyword MajorTopicYN="N">mild symptoms</Keyword><Keyword MajorTopicYN="N">severe symptoms</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360263</ArticleId><ArticleId IdType="pmc">PMC11445176</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1419886</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center for Systems Science and Engineering at Johns Hopkins University . COVID-19 dashboard. (2022). Available at:
https://coronavirus.jhu.edu/map.html (Accessed August 22, 2023).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . CDC Museum COVID-19 timeline. (2022). Available at:
https://www.cdc.gov/museum/timeline/covid19.html (Accessed October 2, 2022).</Citation></Reference><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. . First case of 2019 novel coronavirus in the United States. N Engl J Med. (2020) 382:929–36. doi: 10.1056/NEJMoa2001191, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001191</ArticleId><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft E. Overview of variants in countries. (2022). Available at:
https://covariants.org/per-country (Accessed May 30, 2022).</Citation></Reference><Reference><Citation>Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2—what do they mean? JAMA. (2021) 325:529–31. doi: 10.1001/jama.2020.27124, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.27124</ArticleId><ArticleId IdType="pubmed">33404586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. . Clinical severity of, and effectiveness of Mrna vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. (2022) 376:e069761. doi: 10.1136/bmj-2021-069761, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069761</ArticleId><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Baggs J, Marquez P, Abara WE, Baumblatt J, Blanc PG, et al. . Safety monitoring of COVID-19 mRNA vaccine second booster doses among adults aged ≥50 years—United States, March 29, 2022–July 10, 2022. MMWR Morb Mortal Wkly Rep. (2022) 71:971–6. doi: 10.15585/mmwr.mm7130a4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7130a4</ArticleId><ArticleId IdType="pmc">PMC9345177</ArticleId><ArticleId IdType="pubmed">35900925</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . COVID data tracker. (2022). Available at:
https://covid.cdc.gov/covid-data-tracker/#datatracker-home (Accessed July 22, 2022).</Citation></Reference><Reference><Citation>Bouzid D, Visseaux B, Kassasseya C, Daoud A, Fémy F, Hermand C, et al. . Comparison of patients infected with delta versus omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med. (2022) 175:831–7. doi: 10.7326/M22-0308, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0308</ArticleId><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the Zoe Covid study. Lancet. (2022) 399:1618–24. doi: 10.1016/S0140-6736(22)00327-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. . COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. (2022) 29:82. doi: 10.1186/s12929-022-00853-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00853-8</ArticleId><ArticleId IdType="pmc">PMC9569411</ArticleId><ArticleId IdType="pubmed">36243868</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J, Jeong H, Kim BH, An S, Yang HR, Kim S. Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea. PLoS One. (2023) 18:e0290154. doi: 10.1371/journal.pone.0290154</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0290154</ArticleId><ArticleId IdType="pmc">PMC10431655</ArticleId><ArticleId IdType="pubmed">37585419</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. . Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. (2021) 326:2043–2054. doi: 10.1001/jama.2021.19499</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.19499</ArticleId><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer O. COVID-19: unvaccinated face 11 times risk of death from delta variant, CDC data show. BMJ. (2021) 374:n2282. doi: 10.1136/bmj.n2282, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2282</ArticleId><ArticleId IdType="pubmed">34531181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al. . Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy. Vaccine. (2021) 9:1195. doi: 10.3390/vaccines9101195, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101195</ArticleId><ArticleId IdType="pmc">PMC8537675</ArticleId><ArticleId IdType="pubmed">34696303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva M, Irving SA, et al. . Waning 2-dose and 3-dose effectiveness of Mrna vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance—vision network, 10 states, August 2021–January 2022. Morb Mortal Wkly Rep. (2022) 71:255–63. doi: 10.15585/mmwr.mm7107e2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7107e2</ArticleId><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalization on and death with the delta variant in the USA. Lancet Infect Dis. (2021) 21:1629–30. doi: 10.1016/S1473-3099(21)00685-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00685-X</ArticleId><ArticleId IdType="pmc">PMC8612715</ArticleId><ArticleId IdType="pubmed">34838221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WH, Cai HL, Yan HC, Wang H, Sun HM, Wei YY, et al. . Protective effectiveness of previous infection against subsequent SARS-CoV-2 infection: systematic review and meta-analysis. Front Public Health. (2024) 12:1353415. doi: 10.3389/fpubh.2024.1353415, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2024.1353415</ArticleId><ArticleId IdType="pmc">PMC11222391</ArticleId><ArticleId IdType="pubmed">38966699</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Forecasting Team . Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. (2023) 401:833–42. doi: 10.1016/s0140-6736(22)02465-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. COVID-19: runny nose, headache, and fatigue are commonest symptoms of omicron, early data show. BMJ. (2021) 375:n3103. doi: 10.1136/bmj.n3103</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n3103</ArticleId><ArticleId IdType="pubmed">34916215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball S. Covid hospitalizations have doubled since May as omicron BA.5 sweeps U.S., but deaths remain low. CNBC. (2022). Available at:
https://www.cnbc.com/2022/07/12/covid-hospitalizations-have-doubled-since-may-as-omicron-bapoint5-sweeps-us-but-deaths-remain-low.html (Accessed August 22, 2022).</Citation></Reference><Reference><Citation>Lin S, Deng X, Ryan I, Zhang K, Zhang W, Oghaghare E, et al. . COVID-19 symptoms and deaths among healthcare workers, United States. Emerg Infect Dis. (2022) 28:1624–41. doi: 10.3201/eid2808.212200, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2808.212200</ArticleId><ArticleId IdType="pmc">PMC9328912</ArticleId><ArticleId IdType="pubmed">35798004</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . COVID-19 vaccine boosters. (2022). Available at:
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?s_cid=11754:additional%20covid%20booster:sem.ga:p:RG:GM:gen:PTN:FY22 (Accessed July 22, 2022).</Citation></Reference><Reference><Citation>Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu QB, et al. . Differences in incidence and fatality of COVID-19 by SARS-CoV-2 omicron variant versus delta variant in relation to vaccine coverage: a world-wide review. J Med Virol. (2022) 95:e28118. doi: 10.1002/jmv.28118</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28118</ArticleId><ArticleId IdType="pmc">PMC9537802</ArticleId><ArticleId IdType="pubmed">36056540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Cho K, Song J, Rahmati M, Koyanagi A, Lee SW, et al. . The case fatality rate of COVID-19 during the delta and the omicron epidemic phase: a meta-analysis. J Med Virol. (2023) 95:e28522. doi: 10.1002/jmv.28522, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28522</ArticleId><ArticleId IdType="pubmed">36691933</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashedi R, Samieefar N, Akhlaghdoust M, Mashhadi M, Darzi P, Rezaei N. Delta variant: the new challenge of COVID-19 pandemic, an overview of epidemiological, clinical, and immune characteristics. Acta Biomed. (2022) 93:e2022179. doi: 10.23750/abm.v93i1.12210</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v93i1.12210</ArticleId><ArticleId IdType="pmc">PMC8972886</ArticleId><ArticleId IdType="pubmed">35315394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrenn JO, Pakala SB, Vestal G, Shilts MH, Brown HM, Bowen SM, et al. . COVID-19 severity from omicron and delta SARS-CoV-2 variants. Influenza Other Respir Viruses. (2022) 16:832–6. doi: 10.1111/irv.12982, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12982</ArticleId><ArticleId IdType="pmc">PMC9111734</ArticleId><ArticleId IdType="pubmed">35415869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MK, Lee B, Choi YY, Um J, Lee KS, Sung HK, et al. . Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea. J Korean Med Sci. (2022) 37:e31. doi: 10.3346/jkms.2022.37.e31, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e31</ArticleId><ArticleId IdType="pmc">PMC8763884</ArticleId><ArticleId IdType="pubmed">35040299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. . SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature. (2021) 599:114–9. doi: 10.1038/s41586-021-03944-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfe G, Perna S, Shukla A. Effectiveness of COVID-19 vaccines and their challenges (review). Exp Ther Med. (2021) 22:1407. doi: 10.3892/etm.2021.10843, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10843</ArticleId><ArticleId IdType="pmc">PMC8524740</ArticleId><ArticleId IdType="pubmed">34676000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. . Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. (2021) 385:1393–400. doi: 10.1056/NEJMoa2114255, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nka AD, Ka AC, Bouba Y, ENJ S, MCT T, Takou D, et al. . Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: a systematic review and meta-analysis protocol. PLoS One. (2022) 17:e0272839. doi: 10.1371/journal.pone.0272839</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272839</ArticleId><ArticleId IdType="pmc">PMC9362926</ArticleId><ArticleId IdType="pubmed">35943981</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A, Cuadrado C, Undurraga EA, García C, Nájera M, Bertoglia MA, et al. . Effectiveness of the second COVID-19 booster against omicron: a large-scale cohort study in Chile. Nat Commun. (2023) 14:6836. doi: 10.1038/s41467-023-41942-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41942-y</ArticleId><ArticleId IdType="pmc">PMC10603055</ArticleId><ArticleId IdType="pubmed">37884492</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Dargham SR, Coyle P, Yassine HM, al-Khal A, Abou-Samra AB, et al. . COVID-19 disease severity in persons infected with omicron BA.1 and BA.2 sublineages and association with vaccination status. JAMA Intern Med. (2022) 182:1097–9. doi: 10.1001/jamainternmed.2022.3351, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.3351</ArticleId><ArticleId IdType="pmc">PMC9396464</ArticleId><ArticleId IdType="pubmed">35994264</ArticleId></ArticleIdList></Reference><Reference><Citation>New York State Department of Health . COVID-19 reinfection data. (2022). Available at:
https://coronavirus.health.ny.gov/covid-19-reinfection-data (Accessed August 22, 2022).</Citation></Reference><Reference><Citation>Blum D. How to stay safe from Covid this holiday season. New York Times. (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>